There are currently 1310 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Healthcare of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis
Recruiting
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
08/02/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Juvenile Spondyloarthritis
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
Recruiting
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/02/2024
Locations: GSK Investigational Site, Atlanta, Georgia
Conditions: Respiratory Syncytial Virus Infections
Type 1 Diabetes Education and Support Study
Recruiting
Diabetes distress has been identified as one of the largest contributors to the racial disparity in glycemic control that disproportionately burdens Black patients ages 18-30 years with type 1 diabetes (T1D). In order to combat this issue, this study assesses the feasibility of the culturally tailored intervention T1DES and evaluates the effect of the T1DES intervention on diabetes outcomes in a pilot randomized clinical trial among Black young adults with T1D.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
08/02/2024
Locations: Kaiser Permanente Georgia, Atlanta, Georgia
Conditions: Type1diabetes
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2024
Locations: Piedmont Heart Institute, Atlanta, Georgia +1 locations
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Recruiting
This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)
Gender:
ALL
Ages:
Between 2 years and 26 years
Trial Updated:
08/01/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Solid Tumor
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Recruiting
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2024
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Recruiting
Smoke Free SafeCare (SFSC) is a proposed braided intervention consisting of two evidence-based interventions: Some Things are Better Outside (STBO), aimed at promoting smoke free home rules, and SafeCare, aimed at reducing child maltreatment and improving mother and child outcomes. STBO is effective in creating smoke free homes and reducing second-hand smoke in low-SES (socioeconomic status) households. SafeCare is an effective parent training program that is broadly disseminated in child protec... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/01/2024
Locations: Georgia State University, Atlanta, Georgia
Conditions: Child Maltreatment, Smoking Behaviors
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Recruiting
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/01/2024
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma
Genetic Collection Protocol
Recruiting
This study involves the one-time collection of whole blood or saliva samples for the extraction and storage of DNA for use in ongoing and future ChiLDReN studies.
Gender:
ALL
Ages:
Between 24 hours and 25 years
Trial Updated:
07/30/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Liver Diseases
InSpace Accelerated Rehabilitation Study
Recruiting
This is a prospective, parallel group, open-label, multi- center, randomized study to assess two accelerated rehabilitation programs for use with the InSpace device in the treatment of full thickness Massive, Irreparable Rotator Cuff Tears (MIRCTs) performed during an arthroscopic procedure.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/30/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Rotator Cuff Tears
Perilunate Management
Recruiting
Perilunate injuries can be debilitating injuries that involve the carpus. These can limit patients' functionality both acutely and long-term. Not only do their potential for nerve injury increase risk of lasting weakness and chronic pain, but their complex surrounding involving the carpus also leads to potential for misalignment when healing. The approach for treating perilunate injuries often relies on internal fixation, prompting the need for surgery. However, there is no clear recommendation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Grady Memorial Hospital, Atlanta, Georgia
Conditions: Perilunate Injury
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
Recruiting
The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolera... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/27/2024
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Phenylketonuria